PTC
TBPH

Petrus Trust Company’s Theravance Biopharma TBPH Stock Holding History

Petrus Trust Company’s Portfolio TBPH Stock Details TBPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-12,047
Closed -$176K – 145
2025
Q3 		$176K Buy
+12,047
New +$152K 0.02% 119
2024
Q3 		– Sell
-81,449
Closed -$691K – 741
2024
Q2 		$691K Buy
81,449
+19,421
+31% +$175K 0.06% 107
2024
Q1 		$556K Buy
+62,028
New +$575K 0.05% 171

Other funds holding TBPH

MAP
Madison Avenue Partners New York $2.32B AUM 132.6% 1-Year Est. Return
WAM
Weiss Asset Management Boston, Massachusetts $9.54B AUM 55.06% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ICM
Irenic Capital Management New York $2.08B AUM 19.87% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return

Petrus Trust Company's TBPH Position: Q4 2025 in Review

Petrus Trust Company sold out of Theravance Biopharma (TBPH) in Q4 2025, closing a stake of 12,047 shares — an estimated $176K sold.

Petrus Trust Company first reported a position in TBPH in Q1 2024 and held it in 3 quarters. The position peaked at $691K in Q2 2024. 169 funds tracked by Wall St. Rank hold TBPH as of Q4 2025.

  • Petrus Trust Company reported no remaining Theravance Biopharma position as of Q4 2025 after selling out during the quarter.
  • Petrus Trust Company sold 12,047 Theravance Biopharma shares in Q4 2025, an estimated $176K.
  • Petrus Trust Company first reported a position in Theravance Biopharma in Q1 2024 and held it in 3 quarters.
  • Petrus Trust Company's Theravance Biopharma position peaked at $691K in Q2 2024.
  • 169 funds tracked by Wall St. Rank held Theravance Biopharma as of Q4 2025.

Based on Petrus Trust Company's 13F filing for Q4 2025, filed 17 Feb 2026.